Prescient Therapeutics

Prescient Therapeutics EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Prescient Therapeutics (PTX.AX) as of Nov 22, 2026 is -6.93. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -7.17 — a change of -3.36% (higher).

EV/FCF

-6.93

YoY

-3.36%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Prescient Therapeutics is 2026 -6.93 . EV/FCF (Enterprise Value to Free Cash Flow) of Prescient Therapeutics was 2025 -7.17 . It decreases by -3.36% higher compared to the previous year.

The Prescient Therapeutics EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-11.76 AUD
Jan 1, 2020
-22.27 AUD
Jan 1, 2021
-10.81 AUD
Jan 1, 2022
-10.79 AUD
Jan 1, 2023
-5.97 AUD
Jan 1, 2024
-6.04 AUD
Jan 1, 2025
-7.17 AUD
Jan 1, 2026
-6.93 AUD
The Prescient Therapeutics EV/FCF history
YEAREV/FCFYoY
-6.93-3.36%
-7.17+18.71%
-6.04+1.19%
-5.97-44.68%
-10.79-0.12%
-10.81-51.48%
-22.27+89.34%
-11.76-52.65%
-24.85+59.04%
-15.62-50.39%
-31.49+50.57%
-20.91-51.71%
-43.31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prescient Therapeutics Stock analysis

What does Prescient Therapeutics do? Prescient Therapeutics Ltd is an Australian biotechnology company focused on developing novel cancer therapies. The company was founded in 2006. Its business model is based on leveraging modern technologies and research findings to develop innovative solutions for cancer treatment. Prescient Therapeutics operates in two segments: drug development and research services. The company collaborates closely with leading scientists and medical institutions to utilize the latest advancements in cancer research and bring new drugs to the market. One of its products, PTX-200, is a novel inhibitor of protein kinase CK2 that has shown efficacy in clinical studies against various types of cancer. Another important product is OmniCAR, a next-generation CAR-T cell therapy that allows for selective recognition and destruction of cancer cells. Prescient Therapeutics aims to solidify its position as a leading provider of innovative cancer treatments through a rigorous validation strategy and collaboration with doctors and patients. The company has made significant progress in the development of new cancer therapies, holding numerous patents and establishing partnerships with leading medical institutions. Its goal is to meet the unmet needs of cancer patients and create a better future for cancer therapy. Prescient Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prescient Therapeutics stock

EV/FCF (Enterprise Value to Free Cash Flow) of Prescient Therapeutics is -6.93 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Prescient Therapeutics changed from -7.17 to -6.93, representing a -3.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Prescient Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Prescient Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Prescient Therapeutics

All Key Metrics — Prescient Therapeutics